N-ACETYLCYSTEINE AS A POTENTIAL TREATMENT FOR METHAMPHETAMINE DEPENDENCE

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 采用受试者内、双盲、安慰剂对照设计，20名受试者将在安慰剂、NAC 1800 mg和NAC 3600 mg治疗期间完成手术。 研究药物治疗2天后，将使用我们新开发的虚拟现实（VR）设备，在将参与者暴露于MA和中性线索之前和之后，使用视觉模拟评级量表评估线索诱导的渴望。 然后，受试者将完成接受10 mg烟熏MA（相当于5 mg IV MA）或安慰剂的非偶然剂量的治疗，然后在接受相同剂量或不接受任何药物之间进行5次选择。其中一节将于上午十时进行，另一节则于下午一时进行。 MA和安慰剂的可用性顺序将在每例受试者中平衡。 他们将吸食MA，鉴于吸食MA的生物利用度约为50%（Harris和同事报告绝对生物利用度为37.4 14.2%（Harris、Boxenbaum等人2003）），我们将在管道中装载10 mg MA，以接近5 mg IV MA的效果。 与NAC治疗相关的MA强化作用的任何改变都将随着MA选择数量的变化而明显。 停用研究药物后，受试者将出院。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Twenty participants will complete procedures during treatment with placebo, NAC 1800mg, and NAC 3600mg, using within-subject, double-blind, placebo-controlled design. After 2 days of treatment with study medication, cue-induced craving will be assessed using visual analogue rating scales prior to and after exposing participants to MA and neutral cues using our newly developed virtual reality (VR) apparatus. Participants will then complete sessions in which they receive a non-contingent dose of 10mg smoked MA (equivalent to 5mg IV MA) or placebo followed by 5 choices between receiving identical doses or receiving nothing. One session will be conducted at 10am and the other at 1pm. The order of availability of MA and placebo will be counterbalanced within each participant. They will smoke the MA, and given the bioavailability of smoked MA is about 50% (Harris and colleagues reported absolute bioavailability of 37.4 14.2% (Harris, Boxenbaum et al. 2003)) we will load the pipe 10mg MA to approximate the effects of 5mg IV MA. Any alterations in the reinforcing effects of MA associated with NAC treatment will be evident as changes in the number of choices made for MA. After discontinuation of study medication participants will be discharged.